Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Neuroblastoma 5Osteosarcoma 4Prostatic Neoplasms 3Multiple Myeloma 3Breast Neoplasms 3With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Neuroectodermal Tumors, Primitive 1Neoplasms, Plasma Cell 1Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Hodgkin Disease 1Chondrosarcoma 1CLDN18.2-positive Gastric Adenocarcinoma 1Bone Diseases 1Adenocarcinoma 1

Interventions

radium Ra 223 dichloride 1cabozantinib 1Zoledronic Acid 1Paclitaxel 1BHQ880 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Bone Diseases × Zoledronic Acid × Clear all
NCT00741377 2013-02-18

A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients

Novartis

Phase 1 Completed
28 enrolled
Plasma cell

Bone Diseases, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡